COVID-19 Vaccine

According to the CDC, everyone ages 6 months and older is eligible and encouraged to get a COVID-19 vaccine. Make sure you stay up to date with primary series doses and boosters.

The Food and Drug Administration (FDA) authorized four COVID-19 vaccines in the United States. View the Vaccine Fact Sheets below.

  1. Pfizer-BioNTech mRNA vaccine
  2. Moderna mRNA vaccine
  3. Novavax protein subunit vaccine
  4. Johnson & Johnson/Janssen (J&J) viral vector vaccine ( As of May 7, 2023, J&J COVID-19 vaccine has expired and is no longer available for use in the U.S.)

The CDC maintains a current COVID-19 vaccine schedule, including bivalent mRNA boosters. The number of doses varies by age, vaccine, and previously received COVID-19 vaccines.

Click the tabs to see CDC's vaccination schedule for your age and situation. Talk to your healthcare provider for additional guidance.

Vaccination Schedule for Most People

This section is for most people. For people who are moderately or severely immunocompromised, view the Vaccination Schedule for People who are Moderately or Severely Immunocompromised.

6 months-4 years

Unvaccinated children ages 6 months–4 years are recommended to receive either:

  • 2 Moderna bivalent mRNA vaccine doses (4 or more weeks apart) or
  • 3 Pfizer bivalent mRNA vaccine doses (give 2nd dose at least 3 weeks after 1st dose and give 3rd dose at least 8 weeks after 2nd dose).

Children ages 6 months–4 years who previously received only monovalent doses are recommended to receive 1 or 2 bivalent mRNA vaccine doses depending on vaccine product.

COVID-19 vaccination history

Authorized Bivalent Vaccine

Number of bivalent doses indicated

Total doses of vaccine

Interval between doses

Unvaccinated

Moderna

2

2

Dose 1 and dose 2: 4–8 weeks

Pfizer BioNTech

3

3

Dose 1 and dose 2: 3–8 weeks

Dose 2 and dose 3: At least 8 weeks

1 dose monovalent Moderna

Moderna

1

2

4-8 weeks after monovalent dose

2 doses monovalent Moderna

Moderna

1

3

At least 8 weeks after last monovalent dose

2 doses monovalent Moderna and 1 dose bivalent Moderna

None; previously received 1 bivalent vaccine dose

0

3

NA

1 dose monovalent Pfizer-BioNTech

Pfizer BioNTech

2

3

Dose 1: 3–8 weeks after monovalent dose

Dose 1 and dose 2: At least 8 weeks

2 doses monovalent Pfizer-BioNTech

Pfizer BioNTech

1

3

At least 8 weeks after last monovalent dose

3 doses monovalent Pfizer-BioNTech

Pfizer BioNTech

1

4

At least 8 weeks after last monovalent dose

2 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTech

None; previously received 1 bivalent vaccine dose

0

3

NA


5 years

Children ages 5 years who are unvaccinated are recommended to receive 1 Pfizer or 2 Moderna bivalent mRNA vaccine doses (4 or more weeks apart). Children ages 5 years who previously received only monovalent doses are recommended to receive 1 bivalent mRNA vaccine dose.

COVID-19 vaccination history

Authorized Bivalent Vaccine

Number of bivalent doses indicated

Total doses of vaccine

Interval between doses

Unvaccinated

Moderna

2

2

Dose 1 and Dose 2: 4–8 weeks

Pfizer BioNTech

1

1

­—

1 dose monovalent Moderna

Moderna

1

2

4–8 weeks after monovalent dose

Pfizer BioNTech

1

2

At least 8 weeks after monovalent dose

2 doses monovalent Moderna

Moderna

1

3

At least 8 weeks after last monovalent dose

Pfizer BioNTech

1

3

At least 8 weeks after last monovalent dose

2 doses monovalent Moderna and 1 dose bivalent mRNA

NA; previously received 1 bivalent vaccine dose

NA

3

NA

1 or more doses monovalent Pfizer-BioNTech

Pfizer-BioNTech

1

2 or more

At least 8 weeks after last monovalent dose

2 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTech

NA; previously received 1 bivalent vaccine dose

NA

3

NA

Ever received 1 dose bivalent Pfizer-BioNTech (regardless of monovalent vaccine history)

NA; previously received 1 bivalent vaccine dose

NA

1 or more

NA


6-11 years

People ages 6 years and older who are unvaccinated or previously received only monovalent vaccine doses are recommended to receive 1 bivalent mRNA vaccine dose.

COVID-19 vaccination history

Authorized Bivalent Vaccine

Number of bivalent doses indicated

Total doses of vaccine

Interval between doses

Unvaccinated

Moderna

1

1

—

Pfizer BioNTech

1

1

—

1 or more doses monovalent mRNA (no doses bivalent mRNA)

Moderna

1

2 or more

At least 8 weeks after last monovalent dose

Pfizer BioNTech

1

2 or more

At least 8 weeks after last monovalent dose

2 or more doses monovalent mRNA and 1 dose bivalent mRNA

NA; previously received 1 bivalent vaccine dose

NA

3 or more

NA

Ever received 1 dose bivalent mRNA (regardless of monovalent vaccine history)

NA; previously received 1 bivalent vaccine dose

NA

1 or more

NA

12 years and older

People ages 12 years and older who are unvaccinated, previously received only monovalent vaccine doses, previously received 1 or more doses of Novavax, or previously received the Johnson and Johnson (Janssen) vaccine are recommended to receive 1 bivalent mRNA vaccine dose.

People ages 65 years and older have the option to receive 1 additional bivalent mRNA vaccine dose at least 4 months after the first dose of a bivalent mRNA vaccine.

COVID-19 vaccination history

Authorized Bivalent Vaccine†

Number of bivalent doses indicated

Total doses of vaccine

Interval between doses

Unvaccinated*

Moderna

1

1

—

Pfizer BioNTech

1

1

—

1 or more doses monovalent mRNA (no doses bivalent mRNA) OR

1 or more doses of Novavax vaccine (no doses bivalent mRNA) OR

1 dose of Johnson and Johnson (Janssen) vaccine (no doses bivalent mRNA)

Moderna

1

2 or more

At least 8 weeks after last monovalent dose

Pfizer BioNTech

1

2 or more

At least 8 weeks after last monovalent dose

1 dose of Johnson and Johnson (Janssen) vaccine and 1 or more doses monovalent vaccine

Moderna

1

3 or more

At least 8 weeks after last monovalent dose

Pfizer BioNTech

1

3 or more

At least 8 weeks after last monovalent dose

Younger than 65 and ever received 1 dose bivalent mRNA (regardless of monovalent vaccine history)

NA; previously received 1 bivalent vaccine dose

NA

1 or more

NA

65 or older and ever received 1 dose bivalent mRNA (regardless of monovalent vaccine history)

Moderna

1

2 or more

At least 4 months since last bivalent booster dose

Pfizer BioNTech

1

2 or more

At least 4 months since last bivalent booster dose

*People ages 12 years and older who are unable or choose not to get an updated Pfizer-BioNTech or Moderna COVID-19 vaccine can get 2-dose primary series of Novavax separated by 3–8 weeks. 

†People ages 18 years and older who completed primary vaccination using any COVID-19 vaccine may receive 1 monovalent Novavax booster dose at least 6 months after completion of the primary series if they:

  • Have not received any previous booster doses -AND-
  • Are either:
    • Unable to receive an mRNA vaccine (i.e., mRNA vaccine contraindicated or not available) -OR-
    • Unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose

Novavax is not authorized as a booster dose at this time for teens aged 12–17 years.

 

 Vaccination Schedule for People who are Moderately or Severely Immunocompromised 

This section is for people who are moderately or severely immunocompromised. For most people, view the Vaccination Schedule for Most People.

6 months-4 years

Unvaccinated children ages 6 months-4 years who are moderately or severely immunocompromised are recommended to receive 3 bivalent mRNA doses. Children ages 6 months-4 years who previously received only monovalent doses are recommended to receive 1 or 2 bivalent mRNA vaccine doses, depending on the number of monovalent doses already received.

COVID-19 vaccination history

Authorized Bivalent Vaccine

Number of bivalent doses indicated

Total doses of vaccine

Interval between doses

Unvaccinated

Moderna

3

3

Dose 1 and dose 2: 4 weeks

Dose 2 and dose 3: At least 4 weeks

Pfizer BioNTech

3

3

Dose 1 and dose 2: 3 weeks

Dose 2 and dose 3: At least 8 weeks

1 dose monovalent Moderna

Moderna

2

3

Dose 1: 4 weeks after monovalent dose

Dose 1 and dose 2: At least 4 weeks

2 doses monovalent Moderna

Moderna

1

3

At least 4 weeks after last monovalent dose

3 doses monovalent Moderna

Moderna

1

4

At least 8 weeks after last monovalent dose

3 doses monovalent Moderna and 1 dose bivalent Moderna

—

*

—

—

1 dose monovalent Pfizer-BioNTech

Pfizer BioNTech

2

3

Dose 1: 3 weeks after monovalent dose

Dose 1 and dose 2: At least 8 weeks

2 doses monovalent Pfizer-BioNTech

Pfizer BioNTech

1

3

At least 8 weeks after last monovalent dose

3 doses monovalent Pfizer-BioNTech

Pfizer BioNTech

1

4

At least 8 weeks after last monovalent dose

2 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTech

—

*

—

—

3 doses of monovalent Pfizer-BioNTech and 1 bivalent Pfizer-BioNTech dose

—

*

—

—

*People ages 6 months–4 years who are moderately or severely immunocompromised have the option to receive 1 additional dose of a homologous bivalent mRNA vaccine at least 2 months following the last recommended bivalent mRNA COVID-19 vaccine dose. Further additional homologous bivalent dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose.

5 years

Unvaccinated children ages 5 years who are who are moderately or severely immunocompromised are recommended to receive 3 Pfizer or Moderna bivalent mRNA vaccine doses. Children ages 5 years who previously received only monovalent doses are recommended to receive 1 or 2 bivalent mRNA vaccine doses, depending on the number of monovalent doses already received. Children ages 5 years who previously received a bivalent mRNA vaccine dose have the option to receive 1 additional bivalent mRNA dose.

COVID-19 vaccination history

Authorized Bivalent Vaccine

Number of bivalent doses indicated

Total doses of vaccine

Interval between doses

Unvaccinated

Moderna

3

3

Dose 1 and dose 2: 4 weeks

Dose 2 and dose 3: At least 4 weeks

Pfizer BioNTech

3

3

­Dose 1 and dose 2: 3 weeks

Dose 2 and dose 3: At least 4 weeks

1 dose monovalent Moderna

Moderna

2

3

Dose 1: 4 weeks after monovalent dose

Dose 1 and dose 2: At least 4 weeks

2 doses monovalent Moderna

Moderna

1

3

At least 4 weeks after last monovalent dose

3 doses monovalent Moderna

Moderna

1

4

At least 8 weeks after last monovalent dose

Pfizer BioNTech

1

4

At least 8 weeks after last monovalent dose

3 doses monovalent Moderna and 1 dose bivalent mRNA

—

*

—

—

1 dose monovalent Pfizer-BioNTech

Pfizer-BioNTech

2

3

Dose 1: 3 weeks after monovalent dose

Dose 1 and dose 2: At least 4 weeks

2 doses monovalent Pfizer-BioNTech

Pfizer-BioNTech

1

3

At least 4 weeks after last monovalent dose

3 doses monovalent Pfizer-BioNTech

Pfizer-BioNTech

1

4

At least 8 weeks after last monovalent dose

3 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTech

—

*

—

—

*Children ages 5 years who are moderately or severely immunocompromised have the option to receive 1 additional dose of a bivalent mRNA vaccine at least 2 months following the last recommended bivalent mRNA COVID-19 vaccine dose. Further additional bivalent dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose. People in this age group who previously received a dose(s) of Pfizer-BioNTech vaccine are authorized to receive only Pfizer-BioNTech vaccine. Recipients who previously received Moderna vaccine are authorized to receive either bivalent mRNA vaccine.

6-11 years

Children ages 6–11 years who are moderately or severely immunocompromised who are unvaccinated or previously received only monovalent vaccine doses are recommended to receive 1 or more bivalent mRNA vaccine dose(s).

COVID-19 vaccination history

Authorized Bivalent Vaccine

Number of bivalent doses indicated

Total doses of vaccine

Interval between doses

Unvaccinated

Moderna

3

3

Dose 1 and dose 2: 4 weeks

Dose 2 and dose 3: At least 4 weeks

Pfizer BioNTech

3

3

Dose 1 and dose 2: 3 weeks

Dose 2 and dose 3: At least 4 weeks

1 dose monovalent Moderna

Moderna

2

3

Dose 1: 4 weeks after monovalent dose

Dose 1 and dose 2: At least 4 weeks

2 doses monovalent Moderna

Moderna

1

3

At least 4 weeks after last monovalent dose

3 doses monovalent Moderna

Moderna

1

3

At least 8 weeks after last monovalent dose

Pfizer BioNTech

1

3

At least 8 weeks after last monovalent dose

3 doses monovalent Moderna and 1 dose bivalent mRNA

—

*

—

—

1 dose monovalent Pfizer-BioNTech

Pfizer BioNTech

2

3

Dose 1: 3 weeks after monovalent dose

Dose 1 and dose 2: At least 4 weeks

2 doses monovalent Pfizer-BioNTech

Pfizer BioNTech

1

3

At least 4 weeks after last monovalent dose

3 doses monovalent Pfizer-BioNTech

Moderna

1

4

At least 8 weeks after last monovalent dose

Pfizer BioNTech

1

4

At least 8 weeks after last monovalent dose

3 doses monovalent Pfizer-BioNTech and 1 dose bivalent mRNA

—

*

—

—

*Children ages 6–11 years who are moderately or severely immunocompromised have the option to receive 1 additional dose of Moderna COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine at least 2 months following the last recommended bivalent COVID-19 vaccine dose. Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose.

12 years and older

People ages 12 years and older who are unvaccinated, previously received only monovalent vaccine doses, previously received 1 or more doses of Novavax, or previously received the Johnson and Johnson (Janssen) vaccine are recommended to receive 1 or more bivalent mRNA vaccine dose(s).

People ages 65 years and older have the option to receive 1 additional bivalent mRNA vaccine dose at least 4 months after the first dose of a bivalent mRNA vaccine.

COVID-19 vaccination history

Authorized Bivalent Vaccine†

Number of bivalent doses indicated

Total doses of vaccine

Interval between doses

Unvaccinated*

Moderna

3

3

Dose 1 and dose 2: 4 weeks

Dose 2 and dose 3: At least 4 weeks

Pfizer BioNTech

3

3

Dose 1 and dose 2: 3 weeks

Dose 2 and dose 3: At least 4 weeks

1 dose monovalent Moderna

Moderna

2

3

Dose 1: 4 weeks after monovalent dose

Dose 1 and dose 2: At least 4 weeks

2 doses monovalent Moderna

Moderna

1

3

At least 4 weeks after last monovalent dose

3 doses monovalent Moderna

Moderna

1

3

At least 8 weeks after last monovalent dose

Pfizer BioNTech

1

3

At least 8 weeks after last monovalent dose

3 doses monovalent Moderna and 1 dose bivalent mRNA

—

Δ

—

—

1 dose monovalent Pfizer-BioNTech

Pfizer BioNTech

2

3

Dose 1: 3 weeks after monovalent dose

Dose 1 and dose 2: At least 4 weeks

2 doses monovalent Pfizer-BioNTech

Pfizer BioNTech

1

3

At least 4 weeks after last monovalent dose

3 doses monovalent Pfizer-BioNTech

Moderna

1

4

At least 8 weeks after last monovalent dose

Pfizer BioNTech

1

4

At least 8 weeks after last monovalent dose

3 doses monovalent Pfizer-BioNTech and 1 dose bivalent mRNA

—

Δ

—

—

1 or 2 doses of Novavax vaccine

Moderna

1

2 or 3

At least 8 weeks after last monovalent dose

Pfizer BioNTech

1

2 or 3

At least 8 weeks after last monovalent dose

1 dose of Johnson and Johnson (Janssen) vaccine (no doses bivalent mRNA)

Moderna

2

3

Dose 1: At least 4 weeks after last monovalent dose

Dose 1 and dose 2: At least 8 weeks

Pfizer BioNTech

2

3

Dose 1: At least 4 weeks after last monovalent dose

Dose 1 and dose 2: At least 8 weeks

1 dose of Johnson and Johnson (Janssen) and 1 dose bivalent mRNA

—

Δ

—

—

*People 12 years and older who are unable or choose not to get an updated Pfizer-BioNTech or Moderna COVID-19 vaccine can get 2-dose primary series of Novavax separated by 3 weeks. 

†People ages 18 years and older who completed primary vaccination using any COVID-19 vaccine may receive 1 monovalent Novavax booster dose at least 6 months after completion of the primary series if they:

  • Have not received any previous booster doses -AND-
  • Are either:
    • Unable to receive an mRNA vaccine (i.e., mRNA vaccine contraindicated or not available) -OR-
    • Unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose

Novavax is not authorized as a booster dose at this time for teens aged 12–17 years.

ΔPeople ages 12 years and older who are moderately or severely immunocompromised have the option to receive 1 additional dose of Moderna COVID-19 vaccine or Pfizer-BioNTech COVID-19 vaccine at least 2 months following the last recommended bivalent COVID-19 vaccine dose. Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose.

 

Vaccine Fact Sheets

Moderna: English, Español, አማርኛ, العربية, বাংলা, 한국어, Монгол, Pусский, 中文(简体), Tagalog, ไทย, Tiếng Việt

Pfizer-BioNTech: English, Español, አማርኛ, العربية, বাংলা, 한국어, Монгол, Pусский, 中文(简体), Tagalog, ไทย, Tiếng Việt  

Novavax: English, Español, አማርኛ, العربية, বাংলা, 한국어, Монгол, Pусский, 中文(简体), ไทย, Tiếng Việt

Johnson and Johnson/Janssen (J&J): English, Español, አማርኛ, العربية, বাংলা, 한국어, Монгол, Pусский, 中文(简体), ไทย, Tiếng Việt

Find Your Vaccine

COVID-19 Emergency Phase Ends

On May 5, 2023, the World Health Organization declared the end of the global COVID-19 public health emergency. On May 11, 2023, the U.S. COVID-19 Public Health Emergency declaration expired.


With the emergency phase over, efforts shift from emergency response to managing the ongoing COVID-19 pandemic alongside other infectious diseases. 


While the emergency response has ended, there are no changes to the way we can protect ourselves from COVID-19. You still can slow the spread using layered strategies. No single strategy is perfect at preventing the spread of COVID-19. Use as many multiple (overlapping) layers of protection as you can–stay up-to-date with vaccines (including boosters), get tested, and stay home when you’re sick.

Back to top